ClassID:

21596

A61K51/1096 - CPC Classification

Classification description:

Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds; Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins; Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in , and including a radioactive nucleus for use in radiotherapeutic applications

Recent Application in this class:
#1
20260151522
2026-06-04

RADIOPHARMACEUTICAL MOFS FOR MEDICAL IMAGING

#2
20260151520
2026-06-04

CLAUDIN 18.2-TARGETED COMPOUNDS AND USES THEREOF

#3
20260132197
2026-05-14

ANTIBODIES TARGETING CD47 AND USES THEREOF

#4
20260131036
2026-05-14

CD138/SYNDECAN1 ANTIBODIES AND METHODS OF USE THEREOF

#5
20260115336
2026-04-30

MOFS WITH BETA-EMITTERS FOR RADIOTHERAPY

#6
20260077076
2026-03-19

AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO

#7
20260048159
2026-02-19

THERAPEUTIC AGENTS AND USES THEREOF

#8
20260028414
2026-01-29

5T4 BINDING POLYPEPTIDES AND USES THEREOF

#9
20250326856
2025-10-23

HUMANIZED ANTI-CD45 ANTIBODIES AND USES THEREOF

#10
20250319216
2025-10-16

RADIOPHARMCEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS

#11
20250295794
2025-09-25

MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES

#12
20250281654
2025-09-11

METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS

#13
20250228985
2025-07-17

COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME

#14
20250205375
2025-06-26

HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS

#15
20250171379
2025-05-29

RADIOLABELING OF POLYPEPTIDES

#16
20250152760
2025-05-15

RADIOACTIVE COMPLEX OF ANTI-VEGF ANTIBODY, AND RADIOPHARMACEUTICAL

#17
20250144255
2025-05-08

IMPROVED ANTIBODY-PAYLOAD CONJUGATES (APCS) PREPARED BY SITE-SPECIFIC CONJUGATION UTILIZING GENETIC CODE EXPANSION

#18
20250099635
2025-03-27

IIMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES

#19
20250082794
2025-03-13

ANTIMONY CHELATES FOR TARGETED AUGER THERAPY AND IMAGING DIAGNOSTICS

#20
20250082793
2025-03-13

MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME

#21
20250073274
2025-03-06

METHODS FOR TREATING CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES

#22
20250051476
2025-02-13

DLL3 BINDING MOLECULES AND USES THEREOF

#23
20250001019
2025-01-02

METHODS OF TREATING CANCER

#24
20240417452
2024-12-19

ANTI-MESOTHELIN NANOBODIES AND USE THEREOF

#25
20240415990
2024-12-19

USE OF ANTI-B7H3 ANTIBODIES FOR TREATING CANCER IN THE CENTRAL NERVOUS SYSTEM

#26
20240408249
2024-12-12

EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF

#27
20240391849
2024-11-28

RADIOLABELING OF POLYPEPTIDES

#28
20240390532
2024-11-28

RADIOIMMUNOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER

#29
20240366816
2024-11-07

Structural Optimization Method to Improve the Theranostic Performance of Peptide Receptor-Targeted Radionuclide Therapy for Cancers

#30
20240366778
2024-11-07

ANTI-NECTIN-4 ANTIBODY, DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF

#31
20240358867
2024-10-31

REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME

#32
20240342322
2024-10-17

Netrin-1 detection, companion test and therapy based on radiations

#33
20240335573
2024-10-10

RADIONUCLIDE MICROSPHERES AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

#34
20240335558
2024-10-10

ISOLATED POLYPEPTIDE AND USE THEREOF

#35
20240316228
2024-09-26

RADIOACTIVE COMPLEX OF DEGLYCOSYLATED ANTIBODY AND RADIOACTIVE PHARMACEUTICAL PRODUCT

#36
20240307564
2024-09-19

ANTI-CLDN18.2 ANTIBODY CONJUGATES

#37
20240307562
2024-09-19

ANTI-oxMIF RADIOIMMUNOCONJUGATE

#38
20240299601
2024-09-12

RADIOLABELED ANTI-LAG3 ANTIBODIES FOR IMMUNO-PET IMAGING

#39
20240299596
2024-09-12

METHODS AND MATERIALS FOR COMBINING BIOLOGICS WITH MULTIPLE CHELATORS

#40
20240294464
2024-09-05

SYNTHESIS OF RESTRAINED COMPLEXING AGENTS

#41
20240293588
2024-09-05

THERAPEUTIC CONJUGATES

#42
20240293453
2024-09-05

MATERIALS AND METHODS FOR BINDING SIGLEC-3/CD33

#43
20240285818
2024-08-29

RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY

#44
20240261446
2024-08-08

ANTI-CD38 SINGLE DOMAIN ANTIBODIES IN DISEASE MONITORING AND TREATMENT

#45
20240261445
2024-08-08

PRECISION RADIOPHARMACEUTICAL THERAPY OF LYMPHOMA AND OTHER DISEASES

#46
20240261444
2024-08-08

RIGIDIFIED MACROCYCLES, COMPLEXES WITH RADIONUCLIDES, AND USE IN TARGETED RADIOTHERAPY OF CANCER

#47
20240238461
2024-07-18

MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF

#48
20240226311
2024-07-11

Improved immunoglobulin II

#49
20240216557
2024-07-04

RADIOLIGAND BINDING TO ANTI-DLL3 ANTIBODIES FOR PRETARGETED PET IMAGING AND THERAPEUTIC USES THEREOF

#50
20240216556
2024-07-04

PEPTIDE-FC FUSIONS FOR TREATING AMYLOID DISORDERS

#51
20240209089
2024-06-27

CD8 BINDING POLYPEPTIDE AND USE THEREOF

#52
20240209080
2024-06-27

FOLR1 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME

#53
20240207464
2024-06-27

RADIOACTIVE COMPLEX OF ANTI-CD20 ANTIBODY, AND RADIOPHARMACEUTICAL

#54
20240207463
2024-06-27

RADIOACTIVE COMPLEX OF ANTI-EGFR ANTIBODY, AND RADIOPHARMACEUTICAL

#55
20240207462
2024-06-27

IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY

#56
20240207459
2024-06-27

METHOD FOR STORING INTERMEDIATE FOR RADIOPHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION OR STORAGE OF RADIOPHARMACEUTICAL COMPOSITION, INTERMEDIATE COMPOSITION FOR RADIOPHARMACEUTICAL COMPOSITION, AND PHARMACEUTICAL FORMULATION

#57
20240189461
2024-06-13

HUMANISED ANTIBODIES LABELLED WITH RADIONUCLIDES THAT EMIT BETA-RAYS

#58
20240173442
2024-05-30

COMBINATION THERAPY

#59
20240173437
2024-05-30

COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME

#60
20240158528
2024-05-16

ANTI-CD45-BASED CONDITIONING METHODS AND USES THEREOF IN CONJUNCTION WITH GENE-EDITED CELL-BASED THERAPIES

#61
20240156999
2024-05-16

MULTIMERIC CHELATOR COMPOUNDS FOR USE IN TARGETED RADIOTHERAPY

#62
20240139353
2024-05-02

METHODS OF TREATING CANCER

#63
20240124558
2024-04-18

ANTIBODIES BINDING TO SARS-COV-2 VIRUS AND USES THEREOF

#64
20240108766
2024-04-04

LRRC15 ANTIBODIES AND CONJUGATES THEREOF

#65
20240043541
2024-02-08

METHODS FOR TREATING HEMATOLOGIC CANCERS

#66
20240024520
2024-01-25

AUTONOMOUS KNOB DOMAIN PEPTIDES

#67
20240002411
2024-01-04

METHOD FOR PRODUCING RADIOACTIVE ZIRCONIUM COMPLEX

#68
20230416348
2023-12-28

CALRETICULIN NANOBODIES

#69
20230390426
2023-12-07

METHOD FOR PRODUCING RADIOACTIVE ZIRCONIUM COMPLEX

#70
20230390425
2023-12-07

RADIOACTIVE COMPLEXES OF ANTI-HER2 ANTIBODY, AND RADIOPHARMACEUTICAL

#71
20230390424
2023-12-07

TROPHOBLAST GLYCOPROTEIN RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS

#72
20230372550
2023-11-23

MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER

#73
20230372525
2023-11-23

TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS

#74
20230365684
2023-11-16

Materials And Methods For Binding Siglec-3/CD33

#75
20230365683
2023-11-16

Materials And Methods For Binding Siglec-3/CD33

#76
20230364276
2023-11-16

One-Step Labeling of Antibodies to High Specific Activity with Actinium-225

#77
20230340116
2023-10-26

THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM CELLS

#78
20230293738
2023-09-21

B7H3 Antibodies with Chelators

#79
20230256122
2023-08-17

COMBINATION THERAPY FOR TREATING CANCER

#80
20230240637
2023-08-03

SYSTEMS, COMPOSITIONS, AND METHODS FOR LOCAL IMAGING AND TREATMENT OF PAIN

#81
20230218783
2023-07-13

COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME

#82
20230211006
2023-07-06

CYSTEINE LINKED NANOBODY DIMERS

#83
20230201384
2023-06-29

FGFR3-TARGETED RADIOIMMUNOCONJUGATES AND USES THEREOF

#84
20230158162
2023-05-25

MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES

#85
20230122503
2023-04-20

ANTI-PSMA RADIOCONJUGATES AND USES THEREOF

#86
20230120220
2023-04-20

PROCESS FOR SITE-SPECIFIC MODIFICATION OF AN ANTIBODY

#87
20230105344
2023-04-06

STRUCTURAL OPTIMIZATION METHOD TO IMPROVE THE THERANOSTIC PERFORMANCE OF PEPTIDE RECEPTOR-TARGETED RADIONUCLIDE THERAPY FOR CANCERS

#88
20230091468
2023-03-23

SUSTAINED IMMUNOTHERAPY

#89
20230072421
2023-03-09

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

#90
20230052140
2023-02-16

IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF

#91
20230046947
2023-02-16

REACTIVE CONJUGATES

#92
20230011134
2023-01-12

COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER

#93
20220401594
2022-12-22

RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES

#94
20220378956
2022-12-01

Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Use

#95
20220331458
2022-10-20

AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO

#96
20220323620
2022-10-13

RADIOLABELLED ANTIBODY FRAGMENTS FOR USE IN TREATING CANCER

#97
20220304964
2022-09-29

PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE

#98
20220251196
2022-08-11

Low dose antibody-based methods for treating hematologic malignancies

#99
20220251192
2022-08-11

ANTI-CD33 ANTIBODIES FOR TREATING CANCER

#100
20220242969
2022-08-04

ANTIBODY POLYPEPTIDES AND USES THEREOF

#101
20220226514
2022-07-21

METHODS AND COMPOSITIONS FOR DETERMINING THE BIODISTRIBUTION OF ACTIVATABLE ANTI-CD166 ANTIBODY CONJUGATES

#102
20220160908
2022-05-26

CHELATORS AND METHODS OF MAKING AND USING SAME

#103
20220160907
2022-05-26

TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXETAN

#104
20220152228
2022-05-19

COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE

#105
20220143231
2022-05-12

MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF

#106
20220143229
2022-05-12

RADIO-PHARMACEUTICAL COMPLEXES

#107
20220125962
2022-04-28

Antibodies Conjugated With Actinium-225 and Actinium-227, and Related Compositions and Methods

#108
20220125961
2022-04-28

THERAPEUTIC AGENTS AND USES THEREOF

#109
20220118122
2022-04-21

STABILIZED RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN COMPOSITIONS

#110
20220088212
2022-03-24

C-terminal lysine conjugated immunoglobulins

#111
20220064333
2022-03-03

Humanised Anti Kallikrein-2 Antibody

#112
20220062448
2022-03-03

COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME

#113
20220001043
2022-01-06

CD8 IMAGING CONSTRUCTS AND METHODS OF USE THEREOF

#114
20210355210
2021-11-18

Therapeutic and diagnostic methods relating to cancer stem cells

#115
20210275698
2021-09-09

COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME

#116
20210198359
2021-07-01

ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJCTION WITH ACT-BASED CANCER THERAPIES

#117
20210177821
2021-06-17

Androgen Receptor Modulator And Uses Thereof

#118
20210170058
2021-06-10

Modified antibody and radioactive metal-labelled antibody

#119
20210106703
2021-04-15

RADIOIMMUNOCONJUGATES IN COMBINATION WITH OTHER DRUGS AS TREATMENT AGAINST NHL

#120
20210085808
2021-03-25

Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer

#121
20210077048
2021-03-18

SYSTEMS, COMPOSITIONS, AND METHODS FOR LOCAL IMAGING AND TREATMENT OF PAIN

#122
20210030800
2021-02-04

Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using

#123
20210017099
2021-01-21

Radiolabeling of polypeptides

#124
20200398262
2020-12-24

Cu(I)-catalyzed azide-alkyne cycloadditions (CuAAC) ligands and methods for carrying out Cu(I)-catalyzed azide-alkyne cycloaddition reactions

#125
20200385464
2020-12-10

THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM CELLS

#126
20200384137
2020-12-10

18F labeling of proteins using sortases

#127
20200377600
2020-12-03

Methods for treating hematologic cancers

#128
20200317766
2020-10-08

Antibodies to centrin-1, methods of making, and uses thereof

#129
20200308280
2020-10-01

METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES

#130
20200255520
2020-08-13

Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies

#131
20200230266
2020-07-23

THE OPTIMAL 225ACTINIUM--213BISMUTH GENERATOR FOR ALPHA-PARTICLE RADIOIMMUNOTHERAPY

#132
20200197546
2020-06-25

USE OF ANTI-B7H3 ANTIBODIES FOR TREATING CANCER IN THE CENTRAL NERVOUS SYSTEM

#133
20200171165
2020-06-04

ENHANCED TARGETED DELIVERY OF THERAPEUTIC AGENTS

#134
20200155698
2020-05-21

Modular self assembly disassembly (SADA) technologies

#135
20200138986
2020-05-07

THERAPEUTIC AGENTS AND USES THEREOF

#136
20200138969
2020-05-07

Light chain variable regions

#137
20200123270
2020-04-23

Anti-human CEACAM5 antibody Fab fragment

#138
20200102376
2020-04-02

Modified variable domain molecules and methods for producing them

#139
20200085981
2020-03-19

Tumor targeted radionuclide therapy and molecular imaging of HER2+ cancers and other neoplasms

#140
20200040094
2020-02-06

Internalizing human monoclonal antibodies targeting prostate and other cancer cells

#141
20200031942
2020-01-30

Methods to Impair Hematologic Cancer Progenitor Cells and Compounds Related Thereto

#142
20200009263
2020-01-09

C-terminal lysine conjugated immunoglobulins

#143
20190388571
2019-12-26

RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES

#144
20190388540
2019-12-26

HER3 inhibitor for modulating radiosensitivity

#145
20190321498
2019-10-24

Stabilized radio-labeled anti-CD45 immunoglobulin compositions

#146
20190298776
2019-10-03

Amnion coated embolic agents for treating tumors

#147
20190263903
2019-08-29

Low dose antibody-based methods for treating hematologic malignancies

#148
20190247510
2019-08-15

DLL3 MODULATORS AND METHODS OF USE

#149
20190216418
2019-07-18

SYSTEMS, COMPOSITIONS, AND METHODS FOR LOCAL IMAGING AND TREATMENT OF PAIN

#150
20190194087
2019-06-27

Preparation of Pb labeled monoclonal antibodies

#151
20190192703
2019-06-27

TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXETAN

#152
20190192702
2019-06-27

Stabilized radiolabeled anti-CD45 immunoglobulin compositions

#153
20190169312
2019-06-06

Humanised anti kallikrein-2 antibody

#154
20190091354
2019-03-28

Radio-pharmaceutical complexes

#155
20190083662
2019-03-21

IGF-1R monoclonal antibodies and uses thereof

#156
20190083546
2019-03-21

Methods and materials for treating tumors

#157
20190077871
2019-03-14

CD20 BINDING AGENTS AND USES THEREOF

#158
20190046656
2019-02-14

DLL3 MODULATORS AND METHODS OF USE

#159
20190010247
2019-01-10

Therapeutic antibodies and uses thereof

#160
20190008989
2019-01-10

Method for upregulating antigen expression

#161
20180273634
2018-09-27

Antibody polypeptides and uses thereof

#162
20180221505
2018-08-09

Novel Antibody And Use In Diagnosis And Therapy Of Arthropathies

#163
20180200393
2018-07-19

Radiolabelled antibody fragments for use in treating cancer

#164
20180186884
2018-07-05

Anti-VEGFR antibody and uses thereof

#165
20180142016
2018-05-24

Anti-ROR1 antibodies

#166
20180133350
2018-05-17

Systems and methods for determining optimum patient-specific antibody dose for tumor targeting

#167
20180085400
2018-03-29

Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using

#168
20180064825
2018-03-08

ANTI-PD-L1 IMMUNOTOXIN FOR USE IN THERAPY

#169
20180036422
2018-02-08

Methods of delivering DLL3 antibody drug conjugates

#170
20180036421
2018-02-08

Methods of making DLL3 antibody drug conjugates

#171
20180015178
2018-01-18

Anti-DLL3 antibody drug conjugates and methods of use

#172
20170368195
2017-12-28

Anti-DLL3 antibody drug conjugates

#173
20170360956
2017-12-21

Functionalized linear ligands and complexes thereof

#174
20170360955
2017-12-21

Cysteine linked nanobody dimers

#175
20170326259
2017-11-16

Stabilized radiolabeled anti-CD45 immunoglobulin compositions

#176
20170319723
2017-11-09

RADIOIMMUNE COMPLEX, THERANOSTIC AGENT AND KIT

#177
20170307622
2017-10-26

Kits containing DLL3 antibody drug conjugates

#178
20170297008
2017-10-19

Cu(I)-catalyzed azide-alkyne cycloadditions (CuAAC) ligands and methods for carrying out Cu(I)-catalyzed azide-alkyne cycloaddition reactions

#179
20170274094
2017-09-28

Anti-DLL3 antibody drug conjugates

#180
20170266315
2017-09-21

Anti-DLL3 antibody drug conjugates for treating cancer

#181
20170266314
2017-09-21

Methods of making DLL3 antibody drug conjugates

#182
20170266313
2017-09-21

Methods of delivering DLL3 antibody drug conjugates

#183
20170266312
2017-09-21

Anti-DLL3 antibody drug conjugates

#184
20170240643
2017-08-24

Internalizing human monoclonal antibodies targeting prostate and other cancer cells

#185
20170240642
2017-08-24

Anti-CD40 antibodies and methods of treating cancer having CD40+ tumor cells

#186
20170240619
2017-08-24

MODIFIED VARIABLE DOMAIN MOLECULES AND METHODS FOR PRODUCING THEM

#187
20170233480
2017-08-17

ANTI-VEGFR ANTIBODY AND USES THEREOF

#188
20170151356
2017-06-01

Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases

#189
20170112951
2017-04-27

One-step labeling of antibodies to high specific activity with actinium-225

#190
20170107292
2017-04-20

Antagonists for abdominal vasopressin V2 receptor and uses thereof

#191
20170089896
2017-03-30

ALLOGRAFT REJECTION TEST

#192
20170035917
2017-02-09

METHODS OF TREATMENT OF CANCER

#193
20170000901
2017-01-05

Anti-DLL3 antibody drug conjugates for treating cancer

#194
20160369009
2016-12-22

Humanised anti kallikrein-2 antibody

#195
20160354499
2016-12-08

Radio-imaging and radio-therapy of cancer using antibodies to HAAH

#196
20160317683
2016-11-03

Therapeutic Agents and Uses Thereof

#197
20160296648
2016-10-13

Y-90-LABELED ANTI-CD22 ANTIBODY (EPRATUZUMAB TETRAXETAN) IN REFRACTORY/RELAPSED ADULT CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

#198
20160287734
2016-10-06

F labeling of proteins using sortases

#199
20160250348
2016-09-01

Anti-DLL3 antibody drug conjugates

#200
20160228570
2016-08-11

Novel Antibody And Use In Diagnosis And Therapy Of Arthropathies

#201
20160222121
2016-08-04

Methods for treating hematologic cancers

#202
20160220548
2016-08-04

ANDROGEN RECEPTOR MODULATOR AND USES THEREOF

#203
20160206763
2016-07-21

COMPOUNDS AND COMPOSITIONS FOR TARGETING MACROPHAGES AND OTHER MANNOSE-BINDING C-TYPE LECTIN RECEPTOR HIGH EXPRESSING CELLS AND METHODS OF TREATING AND DIAGNOSIS USING SAME

#204
20160199524
2016-07-14

RADIOSENSITIVITY OF FLUOROPHORES AND USE OF RADIOPROTECTIVE AGENTS FOR DUAL-MODALITY IMAGING

#205
20160193372
2016-07-07

METHODS OF IDENTIFYING SURROGATE IMAGING AGENTS FOR ALPHA EMITTER RADIOPHARMACEUTICALS AND THEIR USE IN TREATMENT OF DISEASE

#206
20160184463
2016-06-30

Labeled ligands of anti-Mullerian hormone for diagnosis of endometriosis

#207
20160168261
2016-06-16

IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR

#208
20160136310
2016-05-19

Systems, compositions, and methods for local imaging and treatment of pain

#209
20160130328
2016-05-12

Pathogen Binding Agents Conjugated to Radioisotopes and Uses in Imaging and Therapeutic Applications

#210
20160101199
2016-04-14

METHOD FOR UPREGULATING ANTIGEN EXPRESSION

#211
20160067362
2016-03-10

HELICAL POLYCARBODIIMIDE POLYMERS AND ASSOCIATED IMAGING, DIAGNOSTIC, AND THERAPEUTIC METHODS

#212
20160030606
2016-02-04

Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer

#213
20160029983
2016-02-04

Assessment of labeled probes in a subject

#214
20160024213
2016-01-28

Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain

#215
20150359499
2015-12-17

INTRAOPERATIVE DETECTION OF TUMOR RESIDUES USING BETA-RADIATION AND CORRESPONDING PROBES

#216
20150343087
2015-12-03

Class I anti-CEA antibodies and uses thereof

#217
20150320872
2015-11-12

Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer

#218
20150297762
2015-10-22

Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof

#219
20150283274
2015-10-08

Radioisotope trithiol complexes

#220
20150239983
2015-08-27

High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection

#221
20150210770
2015-07-30

THERAPEUTIC AND DIAGNOSTIC TARGET

#222
20150165075
2015-06-18

Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy

#223
20150132315
2015-05-14

Methods to impair hematologic cancer progenitor cells and compounds related thereto

#224
20150111279
2015-04-23

Class I anti-CEA antibodies and uses thereof

#225
20150093336
2015-04-02

Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages

#226
20150056132
2015-02-26

IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR

#227
20150017096
2015-01-15

HER3 inhibitor for modulating radiosensitivity

#228
20140377173
2014-12-25

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

#229
20140308278
2014-10-16

Class I anti-CEA antibodies and uses thereof

#230
20140286862
2014-09-25

Therapeutic agents and uses thereof

#231
20140286859
2014-09-25

PSMA antibodies and uses thereof

#232
20140235924
2014-08-21

METHOD OF RADIOTHERAPY

#233
20140199236
2014-07-17

Androgen receptor modulator and uses thereof

#234
20140079629
2014-03-20

Class I anti-CEA antibodies and uses thereof

#235
20130323169
2013-12-05

Thiol-ene click chemistry for drug conjugates

#236
20130295008
2013-11-07

Alpha emitting constructs and uses thereof

#237
20130209356
2013-08-15

Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy

#238
20130164214
2013-06-27

Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells

#239
20130071324
2013-03-21

Radioactive metal-labeled anti-cadherin antibody

#240
20130034492
2013-02-07

Class I anti-CEA antibodies and uses thereof

#241
20120301396
2012-11-29

Radioimmunoconjugates and uses thereof

#242
20120141375
2012-06-07

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

#243
20120058047
2012-03-08

METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION

#244
20120039797
2012-02-16

Antibody therapy

#245
20110305631
2011-12-15

Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases

#246
20110189085
2011-08-04

Antibody therapy

#247
20110165081
2011-07-07

PSMA antibodies and uses thereof

#248
20110129415
2011-06-02

Antibody and use in diagnosis and therapy of arthropathies

#249
20110104049
2011-05-05

METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION

#250
20110064653
2011-03-17

Class I anti-CEA antibodies and uses thereof

#251
20100297004
2010-11-25

High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection

#252
20100291113
2010-11-18

Treatment of Proliferative Disorders Using Antibodies to PSMA

#253
20100278727
2010-11-04

Alpha-emitting constructs and uses thereof

#254
20100221175
2010-09-02

Antibody therapy

#255
20100166651
2010-07-01

Radiotherapeutic High Specific Activity Tin-117m and Methods of Use

#256
20100104467
2010-04-29

Production of thorium 228 starting from a natural thorium salt

#257
20100093003
2010-04-15

Methods to impair hematologic cancer progenitor cells and compounds related thereto

#258
20100015044
2010-01-21

Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases

#259
20090098045
2009-04-16

Cytotoxicity mediation of cells evidencing surface expression of MCSP

#260
20090092598
2009-04-09

Antibody therapy

#261
20090053215
2009-02-26

Cytotoxicity mediation of cells evidencing surface expression of CD63

#262
20090030308
2009-01-29

Systems, compositions, and methods for local imaging and treatment of pain

#263
20090010848
2009-01-08

Recombinant Peptides Derived from the Mc3 Anti-BA46 Antibody, Methods of Use Thereof, and Methods of Humanizing Antibody Peptides

#264
20090004105
2009-01-01

Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin

#265
20080286284
2008-11-20

Compositions of PSMA antibodies

#266
20080260635
2008-10-23

Cytotoxicity mediation of cells evidencing surface expression of MCSP

#267
20080213171
2008-09-04

Cancerous disease modifying antibodies

#268
20080063598
2008-03-13

Humanized Antibody

#269
20080019905
2008-01-24

Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection

#270
20070202044
2007-08-30

ANTIBODY THERAPY

#271
20070140961
2007-06-21

Radiotherapeutic high specific activity tin-117m and methods of use

#272
20070037825
2007-02-15

Enhancing the effect of radioimmunotherapy in the treatment of tumors

#273
20060228297
2006-10-12

Thorium-227 for use in radiotherapy of soft tissue disease

#274
20060188439
2006-08-24

Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection

#275
20060153770
2006-07-13

Method of treating tumors

#276
20060002855
2006-01-05

Targeted combination immunotherapy of cancer and infectious diseases

#277
20050226883
2005-10-13

Humanized antibody

#278
20050215472
2005-09-29

PSMA formulations and uses thereof

#279
20050169915
2005-08-04

Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides

#280
20050163707
2005-07-28

Cancer treatment

#281
20050063967
2005-03-24

Cytotoxicity mediation of cells evidencing surface expression of MCSP

#282
20050002940
2005-01-06

Cancerous disease modifying antibodies

#283
17544522
2026-02-17

Lewis Y radioimmunotherapy for the treatment of cancer